Q2 EPS Forecast for Zevra Therapeutics Lifted by Analyst

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Equities research analysts at Roth Capital boosted their Q2 2025 earnings per share estimates for shares of Zevra Therapeutics in a report released on Tuesday, May 13th. Roth Capital analyst J. Aschoff now anticipates that the company will post earnings per share of $2.12 for the quarter, up from their prior estimate of ($0.08). The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.95) per share. Roth Capital also issued estimates for Zevra Therapeutics’ Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.02) EPS, FY2025 earnings at $2.02 EPS, FY2028 earnings at $1.44 EPS and FY2029 earnings at $1.76 EPS.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.15. The firm had revenue of $20.40 million during the quarter, compared to analyst estimates of $16.96 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. During the same quarter last year, the business posted ($0.40) earnings per share.

Other analysts also recently issued research reports about the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $25.00 price target on shares of Zevra Therapeutics in a research note on Wednesday. Citigroup reaffirmed an “outperform” rating on shares of Zevra Therapeutics in a research report on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Zevra Therapeutics in a research report on Thursday, March 13th. Canaccord Genuity Group upped their target price on Zevra Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, March 13th. Finally, Guggenheim upped their target price on Zevra Therapeutics from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday, March 13th. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $22.29.

Zevra Therapeutics Stock Up 2.7%

Shares of NASDAQ ZVRA opened at $8.66 on Friday. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88. The company has a market cap of $473.52 million, a P/E ratio of -4.40 and a beta of 1.87. Zevra Therapeutics has a 1 year low of $4.20 and a 1 year high of $9.76. The firm has a 50-day simple moving average of $7.54 and a two-hundred day simple moving average of $8.08.

Insider Buying and Selling

In other Zevra Therapeutics news, Director John B. Bode purchased 10,000 shares of the firm’s stock in a transaction on Wednesday, March 19th. The stock was bought at an average price of $7.96 per share, with a total value of $79,600.00. Following the transaction, the director now directly owns 40,000 shares of the company’s stock, valued at approximately $318,400. This represents a 33.33% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Zevra Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Barclays PLC raised its stake in Zevra Therapeutics by 292.6% during the 3rd quarter. Barclays PLC now owns 57,599 shares of the company’s stock worth $399,000 after acquiring an additional 42,926 shares in the last quarter. SG Americas Securities LLC increased its stake in Zevra Therapeutics by 54.6% in the fourth quarter. SG Americas Securities LLC now owns 23,500 shares of the company’s stock valued at $196,000 after purchasing an additional 8,302 shares during the period. China Universal Asset Management Co. Ltd. acquired a new position in shares of Zevra Therapeutics during the fourth quarter worth about $94,000. Rhumbline Advisers increased its stake in shares of Zevra Therapeutics by 18.4% during the fourth quarter. Rhumbline Advisers now owns 68,053 shares of the company’s stock worth $568,000 after acquiring an additional 10,573 shares during the period. Finally, IFG Advisors LLC increased its stake in shares of Zevra Therapeutics by 10.0% during the fourth quarter. IFG Advisors LLC now owns 29,050 shares of the company’s stock worth $242,000 after acquiring an additional 2,650 shares during the period. Hedge funds and other institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.